OncoSec Medical IncのRSI
OncoSec Medical IncのRSIは何ですか。
OncoSec Medical IncのRSIは23.68です。
RSIの定義は何ですか。
相対力指数 (The relative strength index, RSI 14)は、一定期間における損益の規模を比較して、証券の価格変動の速度と変動を測る指標です。
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
NASDAQのセクタHealth CareにおけるRSIの企業と比べるOncoSec Medical Inc
OncoSec Medical Incは何をしますか。
oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar
OncoSec Medical Incと類似のrsi
- Novan IncのRSIは23.64です。
- Occidental PetroleumのRSIは23.65です。
- Stabilus S.AのRSIは23.65です。
- Ju Teng InternationalのRSIは23.65です。
- Huaneng Power InternationalのRSIは23.65です。
- Little Green Pharma LtdのRSIは23.67です。
- OncoSec Medical IncのRSIは23.68です。
- The Swatch AGのRSIは23.69です。
- Elys Game TechnologyのRSIは23.73です。
- SOHO ChinaのRSIは23.73です。
- FdのRSIは23.74です。
- West Pharmaceutical ServicesのRSIは23.74です。
- NB Private Equity PartnersのRSIは23.76です。